COFEPRIS medical device registration is the ranking laggard for a reason: most English pages either recycle a generic “LATAM registration” outline or talk about manufacturing in Mexico. U.S. RA leads need a holder checklist — who owns the registro sanitario, which pathway you actually qualify for in 2026, and what must be in Spanish before DIGIPRIS will take the fee.
bioaccess® works from Miami with U.S. MedTech sponsors and keeps trial plus market-access coverage across 19 Latin American and Caribbean markets. Mexico is one market in that footprint, not the only one. Timelines below are experience-based planning ranges for 2026, not COFEPRIS SLAs.
What COFEPRIS registration is
COFEPRIS (Comisión Federal para la Protección contra Riesgos Sanitarios) issues the sanitary registration that must appear on Mexican labeling before you commercially import and sell a device. The legal spine is the Ley General de Salud plus the device reglamento and the applicable NOMs — especially NOM-137-SSA1 (labeling) and NOM-241-SSA1 (GMP / good manufacturing and quality practices for devices). Classification is risk-based Class I / II / III (with IIa/IIb language used in some COFEPRIS materials). Classification drives dossier depth and the standard-route calendar.
A 510(k), De Novo, PMA, or CE certificate is not a Mexican registration. Since September 2025 it can be the ticket onto the abbreviated / equivalence pathway if the authorization comes from an IMDRF- or MDSAP-recognized authority (FDA is the usual U.S. case; Health Canada, TGA, and EU MDR authorizations are the other names reviewers expect). That pathway is a summary dossier plus reliance — not a copy-paste of the FDA decision summary into a Spanish folder with no Mexican holder.
The Mexico Registration Holder is the asset
Foreign manufacturers do not hold the registro sanitario. A Mexico Registration Holder (MRH) — a legally constituted Mexican entity, sometimes still called the authorized representative or sanitary correspondent — files, pays the government fee, and typically owns the number in its name. Transfers are possible and slow. If your exclusive distributor is the MRH, a breakup is a regulatory project.
- Notarized, apostilled letter of representation / power of attorney that states exactly what the MRH may file, modify, renew, and report.
- MRH corporate standing and, where applicable, the establishment notices COFEPRIS expects for the activities they perform.
- A written plan for who is importer of record vs. who is MRH vs. who is distributor. One company can wear two hats. Three hats on a thin distributor is how import permits stall when a person leaves.
- Exit language: how you will transfer the registration if the commercial deal ends. Put it in the appointment, not in a slide.
Pathways and a hedged calendar
- Standard route. Full technical dossier. Published planning windows you will hear in 2026: on the order of 20–30 days for many Class I files, 30–60 for Class II, 60–180 for Class III — after a complete filing. Deficiency letters and workload stretch those numbers. Class III implants should not be promised as a 60-day launch.
- Abbreviated / equivalence route (from 1 September 2025). Summary dossier that leans on a valid FDA or other recognized-market authorization. COFEPRIS has socialized a ~30-day target review across classes. Treat 30 days as a target after completeness, not as door-to-door from the day you hire counsel. Spanish labeling, the MRH pack, and “same device” identity (indications, design, manufacturer) are where abbreviated files die.
March 2025 simplification measures trimmed some administrative steps and compressed certain low-risk reviews. They did not delete the holder requirement.
Dossier checklist
Every pathway
- Device identity: generic and brand names, models, accessories, intended use, and the Mexican class you are claiming.
- MRH letter of representation, apostilled; manufacturer corporate documents as required.
- QMS evidence — ISO 13485 is the practical standard and is the usual way to speak to NOM-241 expectations. MDSAP or a recognized GMP certificate helps; “we are FDA-registered” alone is a thin story.
- Spanish labels and IFU per NOM-137: generic name, origin, lot/serial, expiry if applicable, manufacturer, importer/MRH, and a reserved field for the registration number.
- Proof of payment of the COFEPRIS government fee for the correct clave / modality. Fees are published in MXN and change. Do not freeze a USD “all-in” number from a 2023 blog post.
Standard route extras
- Full technical description, drawings, materials, and specifications.
- Risk analysis (ISO 14971 or equivalent).
- Biocompatibility, electrical, software, and sterility evidence that matches how the device is sold.
- Clinical evidence appropriate to Class III and to novel Class II claims.
Abbreviated route extras
- Certified evidence of the foreign marketing authorization (FDA clearance/approval letter and current listing story, or the equivalent CE/MDR, Health Canada, TGA pack).
- A “sameness” memo: indications, design, labeling claims, and legal manufacturer must match what the reference authority approved. A Mexico-only indication is not an abbreviated file.
- Spanish summary of the foreign review story — not 400 pages of untranslated FDA correspondence.
Validity, renewals, and technovigilance
First registrations remain a five-year instrument in normal practice. As of January 2026, subsequent renewals can be granted for periods of up to ten years — useful if you are already on the market and your holder is stable. Technovigilance reporting stays with the MRH. If your U.S. complaint system does not forward Mexico-reportable events to the MRH on a defined clock, you have a regulatory gap, not a “local admin” task.
FAQ-style close
Can a U.S. company be the registration holder? Not without a Mexican legal entity acting as MRH. Plan the holder before you book the DIGIPRIS slot.
Does the abbreviated pathway replace the MRH? No. It shortens the technical review when the foreign authorization is real and the device is the same. The holder still files.
Is this the same as a COFEPRIS clinical-trial authorization? No. Research ethics and trial import of investigational units are a different authorization. Do not send a 510(k) equivalence pack to a trial desk and expect a sanitary registration number.
How should we budget? Government fees are only the clave. Translations, apostilles, MRH retainers, and one likely deficiency cycle are the project. Hedge the calendar; do not sell the board a single flat USD fee.
Where does a multi-country register-and-hold model live? If the devices are already FDA-cleared (510(k)/PMA) or CE-marked and you want an independent holder rather than a distributor-owned number, bioaccess® describes that separately on the LATAM Launch Subscription market-access page. Mexico is usually sequenced with the abbreviated pack and a holder who is not also your only commercial bet.